These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Di Rocco M; Giona F; Carubbi F; Linari S; Minichilli F; Brady RO; Mariani G; Cappellini MD Haematologica; 2008 Aug; 93(8):1211-8. PubMed ID: 18603565 [TBL] [Abstract][Full Text] [Related]
52. Lysosomal storage diseases: natural history and ethical and economic aspects. Beutler E Mol Genet Metab; 2006 Jul; 88(3):208-15. PubMed ID: 16515872 [TBL] [Abstract][Full Text] [Related]
54. Liposomes - methodology and applications. Ryman BE; Tyrrell DA Front Biol; 1979; 48():549-74. PubMed ID: 387469 [No Abstract] [Full Text] [Related]
55. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease. Sawkar AR; D'Haeze W; Kelly JW Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247 [TBL] [Abstract][Full Text] [Related]
56. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793 [TBL] [Abstract][Full Text] [Related]
58. Ten plus one challenges in diseases of the lysosomal system. Grabowski GA; Whitley C Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545 [TBL] [Abstract][Full Text] [Related]
59. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Aerts JM; Hollak CE; van Breemen M; Maas M; Groener JE; Boot RG Acta Paediatr Suppl; 2005 Mar; 94(447):43-6; discussion 37-8. PubMed ID: 15895711 [TBL] [Abstract][Full Text] [Related]
60. The role of lysosomes in the pathogeny of storage diseases. Hers HG Arch Belg Dermatol Syphiligr; 1972; 28(1):51-7. PubMed ID: 4266285 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]